Identification of new interventions that modulate CD1b lipid presentation, perhaps via modulation of the sphingosine pathway, will have relevance in COPD and other chronic inflammatory lung diseases including Idiopathic Pulmonary Fibrosis and asthma, where the presence of an autoimmune component has also been proposed. This evidence concerns the gene CD1B and asthma.